Perceptions of Biomarker Disclosure Experiences Among ADRD Patients and Family Members: the PARADE Study Experience

These are among the first real-world data pertaining to biomarker-informed diagnostic disclosure of cognitive impairment. The data suggest clinicians may spend longer explaining elevated compared to not elevated amyloid results. Participants with telehealth phone visits reported substantially shorter interactions with the clinician, compared to those seen in-person. Future research should examine how contextual factors influence disclosure experiences.